Michel DuPage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3103986/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BET-bromodomain and EZH2 inhibitor–treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood, 2022, 139, 2983-2997.	1.4	6
2	A PRC1–RNF2 knockout punch for cancer. Nature Cancer, 2021, 2, 996-997.	13.2	0
3	Treg programming and therapeutic reprogramming in cancer. Immunology, 2019, 157, 198-209.	4.4	46
4	Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. Cell Reports, 2018, 23, 3262-3274.	6.4	207
5	Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease. Nature Reviews Immunology, 2016, 16, 149-163.	22.7	409
6	The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation. Immunity, 2015, 42, 227-238.	14.3	253
7	Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nature Immunology, 2015, 16, 188-196.	14.5	347
8	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. Immunity, 2015, 43, 579-590.	14.3	360
9	Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response. Current Opinion in Immunology, 2013, 25, 192-199.	5.5	76
10	Expression of tumour-specific antigens underlies cancer immunoediting. Nature, 2012, 482, 405-409.	27.8	478
11	Endogenous T Cell Responses to Antigens Expressed in Lung Adenocarcinomas Delay Malignant Tumor Progression. Cancer Cell, 2011, 19, 72-85.	16.8	209
12	Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase.	12.0	711

Nature Protocols, 2009, 4, 1064-1072.